With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Acute myeloid leukemia (AML) is a clonal disease caused by genetic abberations occurring
predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a …

Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …

Background Acute myeloid leukemia (AML) remains a devastating disease with a 5-year
survival rate of less than 30%. AML treatment has undergone significant changes in recent …

Opinion statement Acute myeloid leukemia (AML) disease prognosis is poor and there is a
high risk of chemo-resistant relapse for both young and old patients. Thus, there is a …

Abstract Purpose of Review Awareness of the molecular landscape of AML has improved
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …